Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Aikaterini Panopoulou, David A. Cairns, Amy Holroyd, Isabel Nichols, Nikita Cray, Charlotte Pawlyn, Gordon Cook, Mark Drayson, Kevin Boyd, Faith E. Davies, Matthew Jenner, Gareth J. Morgan, Roger Owen, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2023) 141 (14): 1666–1674.

https://doi.org/10.1182/blood.2022018339

Published: 2023

Includes: Supplemental data

Journal Articles

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1561–1563.

https://doi.org/10.1182/blood-2022-160215

Published: 2022

Journal Articles

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Martin F. Kaiser, Pieter Sonneveld, David Cairns, Marc S Raab, Alessandra Larocca, Sarah R Brown, Marc-A. Baertsch, Cong Li, Pellegrino Musto, Kwee Yong, Elias K Mai, Andrea Capra, Gordon Cook, Hartmut Goldschmidt, Mario Boccadoro, Graham Jackson, Niels Weinhold, Francesca Gay

Blood (2022) 140 (Supplement 1): 1556–1558.

https://doi.org/10.1182/blood-2022-160130

Published: 2022

Journal Articles

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1844–1846.

https://doi.org/10.1182/blood-2022-168842

Published: 2022

Journal Articles

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E Davies, Ruth M. de Tute, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Mark T Drayson, Roger G Owen, David Cairns, Gareth J. Morgan, Graham Jackson

Blood (2022) 140 (Supplement 1): 1371–1372.

https://doi.org/10.1182/blood-2022-165376

Published: 2022

Journal Articles

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

John R Jones, David Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Matthew W Jenner, Martin F. Kaiser, Rebecca Mottram, Mark T Drayson, Walter Martin Gregory, Roger G Owen, Kevin Boyd, Gordon Cook, Graham Jackson, Gareth J. Morgan

Blood (2022) 140 (Supplement 1): 1823–1825.

https://doi.org/10.1182/blood-2022-168723

Published: 2022

Journal Articles

The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma

Mohamed Shahin, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A. Walker, Christopher P. Wardell, David Cairns, Tom Menzies, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, John R Jones

Blood (2022) 140 (Supplement 1): 4232–4233.

https://doi.org/10.1182/blood-2022-169628

Published: 2022

Journal Articles

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Isabelle Smith, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S. Houlston, Graham Jackson, Gordon Cook, Guy Pratt, Mark T Drayson, Roger G Owen, Sarah R Brown, Matthew W Jenner

Blood (2022) 140 (Supplement 1): 1833–1835.

https://doi.org/10.1182/blood-2022-159540

Published: 2022

Journal Articles

The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma

Benjamin Dimbleby, Tatiana Zhelezniakova, Alex G Richter, Charlotte Pawlyn, John R Jones, Matthew W Jenner, David Cairns, Tom Menzies, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan, Mark T Drayson

Blood (2022) 140 (Supplement 1): 4299–4300.

https://doi.org/10.1182/blood-2022-169774

Published: 2022

Journal Articles

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah V. Giles, Mark A. Cook, Mark Trehane Drayson, Gordon Cook, Nicola Jane Wright, Simon John North, Stephen Harding, David A. Cairns, Anna Hockaday, Martin F. Kaiser, Paul Moss, Faith E. Davies, Gareth J. Morgan, Graham Jackson, Guy Pratt

Blood (2022) 139 (6): 946–950.

https://doi.org/10.1182/blood.2021013794

Published: 2022

Includes: Supplemental data

Journal Articles

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Tom Menzies, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Roger G Owen, Mark T Drayson, David Cairns, Gareth J. Morgan, Graham Jackson

Blood (2021) 138 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2021-151102

Published: 2021

Journal Articles

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, Dexamethasone (Dara-CVRd), V-Augmented Autologous Stem Cell Transplant (V-ASCT) and Dara-Vrd Consolidation in Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL) Compared with Myeloma XI/XI+ Trial Treatment for Uhir MM: The UK Optimum/Muknine Trial

Martin F. Kaiser, Andrew Hall, Katrina Walker, Nicola Newnham, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Gordon Cook, Guy Pratt, Roger G Owen, Mark T Drayson, Sarah R Brown, Matthew W Jenner

Blood (2021) 138 (Supplement 1): 465.

https://doi.org/10.1182/blood-2021-144990

Published: 2021

Journal Articles

Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

Zoe Craig, Christopher Parrish, Charlotte Pawlyn, Martin F. Kaiser, Catherine Olivier, John R Jones, Mark T Drayson, Roger G Owen, Matthew W Jenner, Gordon Cook, Walter Martin Gregory, Faith E Davies, Gareth J. Morgan, Graham Jackson, David Cairns

Blood (2021) 138 (Supplement 1): 3758.

https://doi.org/10.1182/blood-2021-150631

Published: 2021

Journal Articles

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J Morgan, Ruth M. de Tute, Roger G Owen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt

Blood (2021) 138 (Supplement 1): 820.

https://doi.org/10.1182/blood-2021-150479

Published: 2021

Journal Articles

The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse

John R Jones, Charlotte Pawlyn, Niels Weinhold, Timothy Cody Ashby, Brian A Walker, Christopher P. Wardell, David Cairns, Walter Martin Gregory, Martin F. Kaiser, Gordon Cook, Mark T Drayson, Roger G Owen, Graham Jackson, Faith E Davies, Gareth J. Morgan

Blood (2021) 138 (Supplement 1): 2683.

https://doi.org/10.1182/blood-2021-152123

Published: 2021

Journal Articles

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Matthew W Jenner, Andrew Hall, Sian E Faustini, Alexandra Pitchford, Ruth M. de Tute, Sadie Roberts, Emma Ingleson, Kristian M Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham Jackson, Guy Pratt, Gordon Cook, Roger G Owen, Sarah R Brown, Mark T Drayson, Martin F. Kaiser

Blood (2021) 138 (Supplement 1): 2699.

https://doi.org/10.1182/blood-2021-149268

Published: 2021

Journal Articles

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

Blood (2021) 138 (Supplement 1): 81.

https://doi.org/10.1182/blood-2021-146650

Published: 2021

Journal Articles

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Tom Menzies, Faith E. Davies, Ritika Rana, Jennifer Pinney, Gordon Cook, MD, Walter Martin Gregory, PhD, Matthew W Jenner, John R Jones, MD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Gareth Morgan, MD PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, David Cairns, MSc, PhD, Mark T Drayson, MB ChB, PhD FRCPath

Blood (2020) 136 (Supplement 1): 40–43.

https://doi.org/10.1182/blood-2020-139238

Published: 2020

Journal Articles

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Jessica Caro, MD, David Cairns, MSc, PhD, Tom Menzies, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Eileen M Boyle, MD MSc, Gareth Morgan, MD PhD, Gordon Cook, MB ChB, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Roger G Owen, MD, Walter M Gregory, PhD, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Brian Walker, PhD, Jennifer LJ Heaney, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Faith E. Davies

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-133516

Published: 2020

Journal Articles

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Amy Barber, PhD, John R Jones, MD, Harvey Che, Yann-Vai Le Bihan, Niels Weinhold, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Christopher P. Wardell, PhD MSc, BSc, Hannah Wang, PhD, Martin F. Kaiser, MD FRCP, FRCPath, Graham H Jackson, MD MA, MB BS, FRCP, FRCPath, Faith E. Davies, Rajesh Chopra, MD, Gareth Morgan, MD PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140024

Published: 2020

NARROW

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma

Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

The Impact of Lymphocyte Composition in the Stem Cell Harvest on Blood Lymphocytes 1-2 Weeks Post-Autologous Stem Cell Transplant for Newly Diagnosed Myeloma

Redefining nonmeasurable multiple myeloma using mass spectrometry

Phenotypic High-Risk Disease in the Context of Carfilzomib and Lenalidomide Combination Induction Therapy for Newly Diagnosed Transplant-Eligible Myeloma Patients

Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

The Impact of gain1q on Mutational Structure and Clonal Evolution in a Uniformly Treated High-Risk Series of Patients at First Relapse

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials

The Addition of Carfilzomib to a Lenalidomide-Based Triplet Improves Outcomes in Newly Diagnosed Transplant Eligible Myeloma Patients with Renal Impairment: A Subgroup Analysis of the Myeloma XI Trial

Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma

Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only